《"Follow the Money:" Kevin Mahn on Stock Opportunities Beyond NVDA & MU》
得益于FDA审批进展以及持续的并购趋势，ABVX是一个极具吸引力的收购标的。
Allergan。这只股票自今年年初以来也一直表现不佳。这是一家小型生物技术公司，市值仅为5亿美元。他们正在开发用于治疗癌症和自身免疫性疾病的转基因T细胞疗法。
Allergan. This stock has also been underperforming since the beginning of the year. It is a small biotechnology company, with a market value of only half a billion dollars. They are developing genetically modified T-cell therapies to treat cancer and autoimmune diseases.